NEOTIGASON

This brand name is authorized in Australia, Brazil, Estonia, Spain, Finland, Hong Kong, Croatia, Ireland, Israel, Italy, Lithuania, Malta, Netherlands, New Zealand, Poland, Singapore, Tunisia, Turkey, United Kingdom, South Africa

Active ingredients

The drug NEOTIGASON contains one active pharmaceutical ingredient (API):

1 Acitretin UNII LCH760E9T7 - ACITRETIN

Acitretin, a synthetic aromatic derivative of retinoic acid, has a favourable therapeutic ratio, with a greater and more specific inhibitory effect on psoriasis and disorders of epithelial keratinisation. The usual therapeutic response to acitretin consists of desquamation (with or without erythema) followed by more normal re-epithelialisation. Acitretin is the main active metabolite of etretinate. Read about Acitretin

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
D05BB02	Acitretin	D Dermatologicals → D05 Antipsoriatics → D05B Antipsoriatics for systemic use → D05BB Retinoids for treatment of psoriasis
Discover more medicines within D05BB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 2019G, 2020H
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 537519120008517, 537519120008617, 537519120008717, 537519120008817
Country: EE	Ravimiamet	Identifier(s): 1000731, 1834365, 1834376
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 60302, 60303
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 414953, 456335, 456343, 581493
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 26781, 26782
Country: HK	Department of Health Drug Office	Identifier(s): 39193, 39194
Country: HR	Agencija za lijekove i medicinske proizvode	Identifier(s): HR-H-047281874, HR-H-770001325
Country: IE	Health Products Regulatory Authority	Identifier(s): 19811, 28978, 55595, 61493
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 4540, 4541
Country: IT	Agenzia del Farmaco	Identifier(s): 027480019, 027480021
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1001361, 1088897, 1090627, 1091059, 1093400
Country: MT	Medicines Authority	Identifier(s): AA565/80401
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 29866, 29874
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 5224, 5225
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100046826, 100046832
Country: SG	Health Sciences Authority	Identifier(s): 08391P, 08392P
Country: TN	Direction de la Pharmacie et du Médicament	Identifier(s): 6993161, 6993162
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699638154777, 8699638154784
Country: ZA	Health Products Regulatory Authority	Identifier(s): W/13.4.2/73, W/13.4.2/74